Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease
Background: Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia. Genetic background, particularly polymorphisms of dop...
Main Authors: | Shoko Kakinuma, Minako Beppu, Setsu Sawai, Akitoshi Nakayama, Shigeki Hirano, Yoshitaka Yamanaka, Tatsuya Yamamoto, Chigusa Masafumi, Xiamuxiya Aisihaer, Alimasi Aersilan, Yue Gao, Kenichi Sato, Itoga Sakae, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Satoshi Kuwabara, Tomoaki Tanaka |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | eNeurologicalSci |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405650220300186 |
Similar Items
-
No Association between the rs1799836 Polymorphism of the Monoamine Oxidase B Gene and the Risk of Autism Spectrum Disorders in the Kazakhstani Population
by: Anastassiya V. Perfilyeva, et al.
Published: (2019-01-01) -
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
by: Nicola Tambasco, et al.
Published: (2012-01-01) -
Dysregulation of BET proteins in levodopa-induced dyskinesia
by: David A. Figge, et al.
Published: (2017-06-01) -
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
by: Chang-Qing Zheng, et al.
Published: (2021-06-01) -
Investigation of KATP channels in levodopa -induced dyskinesia (LID)
by: Chia-HuiCheng, et al.
Published: (2018)